{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:53:19Z","timestamp":1791316399435,"version":"4.3.1"},"reference-count":89,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier in their implementation, several early phase clinical trials are currently evaluating CAR-T cell therapies targeting mesothelin, folate receptor a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated and \u201con-target, off-tumor\u201d toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis\/macrophage activation-like syndrome (HLH\/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions.<\/jats:p>","DOI":"10.3390\/diagnostics14080819","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T08:41:06Z","timestamp":1713256866000},"page":"819","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-7706","authenticated-orcid":false,"given":"Clare","family":"Cutri-French","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Nasioudis","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"George","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center at McKinley Campus, 10920 McKinley Dr, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janos L.","family":"Tanyi","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Schepisi, G., Casadei, C., Toma, I., Poti, G., Iaia, M.L., Farolfi, A., Conteduca, V., Lolli, C., Ravaglia, G., and Brighi, N. (2021). Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. Cancers, 13.","DOI":"10.3390\/cancers13040840"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in Ovarian Cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17588359211008399","DOI":"10.1177\/17588359211008399","article-title":"Cell therapies in ovarian cancer","volume":"13","author":"Sarivalasis","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chen, Y.J., Abila, B., and Mostafa Kamel, Y. (2023). CAR-T: What Is Next?. Cancers, 15.","DOI":"10.3390\/cancers15030663"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jha2.338","article-title":"Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice","volume":"3","author":"Sengsayadeth","year":"2022","journal-title":"EJHaem"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"280ps287","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: A race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","article-title":"The association of heavy and light chain variable domains in antibodies: Implications for antigen specificity","volume":"278","author":"Chailyan","year":"2011","journal-title":"FEBS J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","article-title":"Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells","volume":"9","author":"Dwivedi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and Design of Chimeric Antigen Receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12032-022-01824-7","article-title":"The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer","volume":"39","author":"Ding","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhang, X.W., Wu, Y.S., Xu, T.M., and Cui, M.H. (2023). CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. Biomolecules, 13.","DOI":"10.3390\/biom13030465"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Henke, E., Nandigama, R., and Ergun, S. (2019). Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front. Mol. Biosci., 6.","DOI":"10.3389\/fmolb.2019.00160"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2217\/imt-2017-0026","article-title":"Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers","volume":"9","author":"Stashwick","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/imt-2017-0039","article-title":"Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy","volume":"9","author":"Zhang","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.21712","article-title":"The role of folate receptor alpha in cancer development, progression and treatment: Cause, consequence or innocent bystander?","volume":"119","author":"Kelemen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","article-title":"Overexpression of folate binding protein in ovarian cancers","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Siu, M.K., Kong, D.S., Chan, H.Y., Wong, E.S., Ip, P.P., Jiang, L., Ngan, H.Y., Le, X.F., and Cheung, A.N. (2012). Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: Effect on cell proliferation, invasion and clinical outcome. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047201"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40246-016-0096-9","article-title":"The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma","volume":"10","author":"Chang","year":"2016","journal-title":"Hum. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1746-1596-8-190","article-title":"Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma","volume":"8","author":"Wang","year":"2013","journal-title":"Diagn. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"665970","DOI":"10.3389\/fimmu.2021.665970","article-title":"PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies","volume":"12","author":"Jie","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12032-023-02084-9","article-title":"A novel TREM1\/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy","volume":"40","author":"Xu","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1292\/jvms.20-0455","article-title":"Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model","volume":"83","author":"Fu","year":"2021","journal-title":"J. Vet. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Leong, L., Tan, H.L., Cua, S., Yong, K.S.M., Chen, Q., and Choo, A. (2020). Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020381"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies","volume":"28","author":"Sharma","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CJI.0000000000000203","article-title":"Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer","volume":"41","author":"Owens","year":"2018","journal-title":"J. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2023.01.011","article-title":"Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer","volume":"255","author":"Shen","year":"2023","journal-title":"Immunol. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"951143","DOI":"10.3389\/fimmu.2022.951143","article-title":"CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues","volume":"13","author":"Cribioli","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/1535-7163.MCT-23-0008","article-title":"Efficacy and safety of glycosphingolipid SSEA-4 targeting CAR-T cells in an ovarian carcinoma model","volume":"22","author":"Monzo","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","first-page":"717","article-title":"Evaluation of Placental Alkaline Phosphatase Expression as A Potential Target of Solid Tumors Immunotherapy by Using Gene and Protein Expression Repositories","volume":"23","author":"Basiri","year":"2021","journal-title":"Cell J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/1758834011422557","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Sierra","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: The new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: A tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jcp.20007","article-title":"Role of HER receptors family in development and differentiation","volume":"200","author":"Casalini","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"ref_52","first-page":"699","article-title":"Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis\/treatment","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: A multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2007.09.010","article-title":"Mullerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers","volume":"108","author":"Aletti","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"308976","DOI":"10.1155\/2014\/308976","article-title":"Annexin A2: Its molecular regulation and cellular expression in cancer development","volume":"2014","author":"Wang","year":"2014","journal-title":"Dis. Markers"},{"key":"ref_58","first-page":"1771","article-title":"Functions of EpCAM in physiological processes and diseases (Review)","volume":"42","author":"Huang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_59","first-page":"5399","article-title":"PD-L1 expression levels on tumor cells affect their immunosuppressive activity","volume":"18","author":"Zheng","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/glycob\/cwv032","article-title":"Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells","volume":"25","author":"Sivasubramaniyan","year":"2015","journal-title":"Glycobiology"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fu, F., Yang, X., Zheng, M., Zhao, Q., Zhang, K., Li, Z., Zhang, H., and Zhang, S. (2020). Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00202"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1615\/CritRevImmunol.2018019497","article-title":"Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies","volume":"37","author":"Watanabe","year":"2017","journal-title":"Crit. Rev. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","article-title":"Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells","volume":"31","author":"Haas","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S0090-8258(22)01537-2","article-title":"Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)","volume":"166","author":"Tanyi","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e001162","DOI":"10.1136\/jitc-2020-001162","article-title":"alphaPD-1-mesoCAR-T cells partially inhibit the growth of advanced\/refractory ovarian cancer in a patient along with daily apatinib","volume":"9","author":"Fang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1200\/JCO.2023.41.16_suppl.5590","article-title":"Phase 1\/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients","volume":"41","author":"Liao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Castelletti, L., Yeo, D., van Zandwijk, N., and Rasko, J.E.J. (2021). Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00264-1"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2020.38.15_suppl.3014","article-title":"Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma","volume":"38","author":"Annunziata","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e14513","DOI":"10.1200\/JCO.2021.39.15_suppl.e14513","article-title":"Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors","volume":"39","author":"Gutierrez","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Godel","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","first-page":"21","article-title":"CAR T-Cell Therapy: Adverse Events and Management","volume":"10","author":"Adkins","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: An illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Miftakhova, R., Rizvanov, A., and Bulatov, E. (2022). Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers, 14.","DOI":"10.3390\/cancers14041078"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: The next revolution in cancer treatment","volume":"22","author":"Tondok","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)","volume":"159","author":"Park","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","article-title":"Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Res."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/8\/819\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:28:35Z","timestamp":1760106515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/8\/819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":89,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["diagnostics14080819"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14080819","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}